Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group

Page 1 of 5

In this article, we discuss the top 5 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to read our detailed analysis of Green’s history and hedge fund performance, go directly to the Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group.

5. ADC Therapeutics SA (NYSE:ADCT)

Redmile Group’s Stake Value: $204.5 million

Percentage of Redmile Group’s 13F Portfolio: 3.56%

Number of Hedge Fund Holders: 6

ADC Therapeutics SA (NYSE:ADCT) is a Switzerland-based biotechnology company involved in drug discovery and development for solid and hematological cancers.

On September 7, Cantor Fitzgerald analyst Brian Cheng maintained an Overweight rating on ADC Therapeutics SA (NYSE:ADCT) stock with a price target of $46.

According to the third quarter filings of 2021, Redmile Group owned 7.52 million shares of ADC Therapeutics SA (NYSE:ADCT) worth $204.5 million at the end of September 2021.

Page 1 of 5